Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 5/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479076 | 1.00 | HRH3 (0.45) | HRH3HDAC8PLA2G10PLA2G5GAA | |
| SCHEMBL8102889 | 1.00 | HRH3 (0.45) | HRH3HDAC8PLA2G10PLA2G5GAA | |
| SCHEMBL9666858 | 1.00 | HRH3 (0.45) | HRH3HDAC8PLA2G10PLA2G5GAA | |
| SCHEMBL8102895 | 1.00 | HRH3 (0.45) | HRH3HDAC8PLA2G10PLA2G5GAA | |
| SCHEMBL6753882 | 1.00 | HRH3 (0.45) | HRH3HDAC8PLA2G10PLA2G5GAA | |
| SCHEMBL9667791 | 0.89 | HRH3 (0.51) | HRH3CYP1A2CYP2C19 | |
| SCHEMBL9667779 | 0.89 | HRH3 (0.51) | HRH3CYP1A2CYP2C19 | |
| SCHEMBL9478999 | 0.87 | — | — | |
| SCHEMBL9666883 | 0.87 | — | — | |
| SCHEMBL9666919 | 0.85 | CAPN1 (0.39) | HRH3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | claimed |
| WO-2024262349-A1 | COMPOSITION FOR SUPPRESSING OR AMELIORATING DETERIORATION OF COGNITIVE FUNCTION, AND COMPOSITION FOR INHIBITING β-SECRETASE | サントリーホールディングス株式会社 | 2024-12-26 | — | — | WO | claimed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | claimed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | claimed |
| EP-0132392-B1 | ASYMMETRIC SYNTHESIS OF ALPHA-SUBSTITUTED-ALPHA-CYANOMETHYL ALCOHOLS | ICI AUSTRALIA LIMITED (AU) | 1992-01-02 | — | — | EP | claimed |
| EP-0132392-A2 | Asymmetric synthesis of alpha-substituted-alpha-cyanomethyl alcohols | ICI AUSTRALIA LIMITED (AU) | 1985-01-30 | — | — | EP | claimed |
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024262349-A1 | COMPOSITION FOR SUPPRESSING OR AMELIORATING DETERIORATION OF COGNITIVE FUNCTION, AND COMPOSITION FOR INHIBITING β-SECRETASE | サントリーホールディングス株式会社 | 2024-12-26 | — | — | WO | disclosed |
| WO-2024262349-A1 | COMPOSITION FOR SUPPRESSING OR AMELIORATING DETERIORATION OF COGNITIVE FUNCTION, AND COMPOSITION FOR INHIBITING β-SECRETASE | サントリーホールディングス株式会社 | 2024-12-26 | — | — | WO | disclosed |
| EP-3749738-B1 | VISCOELASTIC, SOLID SURFACTANT COMPOSITION | HENKEL AG & CO KGAA (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | disclosed |
| EP-3749739-B1 | DETERGENT COMPOSITION HAVING A FLOW LIMIT | HENKEL AG & CO KGAA (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-11382911-B2 | Plant extract containing diketopiperazine and method for producing same | SUNTORY HOLDINGS LIMITED (JP) | 2022-07-12 | — | — | US | disclosed |
| EP-0132392-B1 | ASYMMETRIC SYNTHESIS OF ALPHA-SUBSTITUTED-ALPHA-CYANOMETHYL ALCOHOLS | ICI AUSTRALIA LIMITED (AU) | 1992-01-02 | — | — | EP | disclosed |
| EP-0304954-A2 | Cyclic dipeptide enantiomers | ICI AUSTRALIA LIMITED (AU) | 1989-03-01 | — | — | EP | disclosed |
| EP-0132392-A2 | Asymmetric synthesis of alpha-substituted-alpha-cyanomethyl alcohols | ICI AUSTRALIA LIMITED (AU) | 1985-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | HRH3 346/4885HDAC8 1245/4885PLA2G10 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.